专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 外观设计

USD1021275S1 Dog crate 有权
公开(公告)号：USD1021275S1
公开(公告)日：2024-04-02
申请号：US29919483
申请日：2023-12-05
申请人： Zhihui Zheng , Zihan Geng , Fang Fang
设计人： Zhihui Zheng , Zihan Geng , Fang Fang
摘要： FIG. 1 is a front, top, and left perspective view of a dog crate showing my new design;
FIG. 2 is a front elevational view thereof;
FIG. 3 is a rear elevational view thereof;
FIG. 4 is a left side elevational view thereof;
FIG. 5 is a right side elevational view thereof;
FIG. 6 is a top plan view thereof;
FIG. 7 is a bottom plan view thereof; and,
FIG. 8 is a rear, bottom, and right perspective view thereof.
The broken lines shown in the drawings represent portions of the dog crate that form no part of the claimed design.

2. 发明授权

US09284330B2 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof 有权
标题翻译： 1,4-二氢 - 萘啶衍生物及其药物组合物及其用途
公开(公告)号：US09284330B2
公开(公告)日：2016-03-15
申请号：US14362735
申请日：2012-12-07
申请人： Rong Chen , Lin Feng , Zhengping Zhang , Fang Fang , Qingli Dong , Fulong Li , Lei Wang , Yao Hua , Shibao Yang , Peng Wang
发明人： Rong Chen , Lin Feng , Zhengping Zhang , Fang Fang , Qingli Dong , Fulong Li , Lei Wang , Yao Hua , Shibao Yang , Peng Wang
IPC分类号： C07D495/14 , C07D471/14 , C07D471/04 , C07D471/12 , C07D491/14
CPC分类号： C07D495/14 , C07D471/04 , C07D471/12 , C07D471/14 , C07D491/14
摘要： Disclosed are 1,4-dihydro-naphthyridine derivatives and pharmaceutical composition and uses thereof. The 1,4-dihydro-naphthyridine derivatives are a compound capable of inhibiting acetylcholinesterase activity and preventing extracellular calcium from flowing into a cell via a calcium channel, i.e., having a dual-activity, which are of potential importance as a pharmaceutical and can be used to prepare the drugs for treating cardiovascular diseases, cerebrovascular diseases and dementia.
摘要翻译：公开了1,4-二氢 - 萘啶衍生物及其药物组合物及其用途。 1,4-二氢 - 萘啶衍生物是能够抑制乙酰胆碱酯酶活性并防止细胞外钙通过钙通道流入细胞的化合物，即具有作为药物具有潜在重要性的双重活性，可以是用于制备治疗心血管疾病，脑血管疾病和痴呆症的药物。

3. 发明授权

US08729303B2 2,2′,6,6′-tetrasubstituted aminophosphine ligand and its synthesis method 有权
标题翻译： 2,2'，6,6'-四取代氨基膦配体及其合成方法
公开(公告)号：US08729303B2
公开(公告)日：2014-05-20
申请号：US12377000
申请日：2007-08-10
申请人： Wanbin Zhang , Fang Xie , Fang Fang
发明人： Wanbin Zhang , Fang Xie , Fang Fang
IPC分类号： C07F9/02
CPC分类号： C07F9/46
摘要： The present invention relates to a 2,2′,6,6′-tetrasubstituted aminophosphine ligand and its synthesis method. The structure of the ligand is shown as below. Its synthesis method comprises: Step (1) coupling 2,6-dinitrochlorobenzene as the starting material to obtain 2,2′,6,6′-tetranitrobiphenyl; Step (2): hydrogenating the 2,2′,6,6′-tetranitrobiphenyl with Pd/C to obtain 2,2′,6,6′-tetraminobiphenyl; Step (3): reacting the 2,2′,6,6′-tetraminobiphenyl with a phosphine halide to obtain the 2,2′,6,6′-tetrasubstituted aminophosphine ligand. The ligand of the present invention is an achiral compound, and its preparation method is simple. The ligand can be converted to a chiral bimetallic catalyst with single configuration eventually through introduction of external chirality. Moreover, the ligand can be used in various asymmetric reaction catalyzed by metals with high reactivity and stereoselectivity.
摘要翻译：本发明涉及2,2'，6,6'-四取代氨基膦配体及其合成方法。配体的结构如下所示。其合成方法包括：步骤（1）以2,6-二硝基氯苯为原料，得到2,2'，6,6'-四硝基联苯; 步骤（2）：用Pd / C氢化2,2'，6,6'-四硝基二苯并得到2,2'，6,6'-四氨基联苯; 步骤（3）：使2,2'，6,6'-四磺酰联苯与卤化膦反应，得到2,2'，6,6'-四取代氨基膦配体。本发明的配体是非手性化合物，其制备方法简单。最终可以通过引入外部手性将配体转化为具有单一配置的手性双金属催化剂。此外，配体可用于由具有高反应性和立体选择性的金属催化的各种不对称反应中。

4. 发明申请

US20130156703A1 Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract 审中-公开
公开(公告)号：US20130156703A1
公开(公告)日：2013-06-20
申请号：US13769095
申请日：2013-02-15
申请人： Fang Fang , David Wurtman , Ron Moss , Michael Malakhov
发明人： Fang Fang , David Wurtman , Ron Moss , Michael Malakhov
IPC分类号： A61K38/47
CPC分类号： A61K38/47 , A61K9/0014 , A61K9/0019 , A61K9/0043 , A61K9/0053 , A61K9/0073 , A61K9/06 , A61K31/05 , A61K31/198 , A61K31/4172 , A61K31/7016 , A61K33/06 , A61K33/14 , A61K38/1808 , A61K45/06 , A61K47/02 , A61K47/22 , A61K47/26 , A61K47/32 , A61K47/34 , A61K49/0008 , C07K14/485 , C07K2319/00 , C12N9/2402 , C12N9/2477 , C12Q1/34 , C12Y302/01018 , G01N2500/00 , G01N2800/122 , A61K2300/00
摘要： The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

5. 发明授权

US07696324B2 Humanized antibodies 失效
标题翻译：人源化抗体
公开(公告)号：US07696324B2
公开(公告)日：2010-04-13
申请号：US11519322
申请日：2006-09-11
申请人： Fang Fang , Lori Kohlstaedt , John Reno
发明人： Fang Fang , Lori Kohlstaedt , John Reno
IPC分类号： C07K16/28 , C12P21/08
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2821 , C07K2317/24 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y02A50/412
摘要： Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of binding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of binding an ICAM-1 epitope are further provided.
摘要翻译：提供了结合ICAM-1的人源化抗体。抗体包括选自：SEQ ID NO：1和3（HumA）的那些; SEQ ID NO：5和7（HumB）; SEQ ID NO：9和11（HumC）; SEQ ID NO：13和15（HumD）; SEQ ID NO：17和19（HumE）; SEQ ID NO：21和23（HumF）; SEQ ID NO：25和27（HumG）; SEQ ID NO：29和31（HumH）; 和SEQ ID NO：33和35（HumI）。还提供了能够结合ICAM-1表位的人源化抗体的子序列。还提供了使用能够结合ICAM-1表位的人源化抗体抑制细胞病原体感染（例如HRV）的方法。

6. 发明申请

US20070190163A1 Technology for preparation of macromolecular microspheres 审中-公开
标题翻译：高分子微球的制备技术
公开(公告)号：US20070190163A1
公开(公告)日：2007-08-16
申请号：US11657812
申请日：2007-01-24
申请人： Michael Malaknov , Fang Fang
发明人： Michael Malaknov , Fang Fang
IPC分类号： C07K1/02 , A61K9/16
CPC分类号： A61K9/1682 , A61K9/0073 , A61K9/14 , A61K9/1617 , A61K9/1647 , A61K9/19 , A61K38/18 , A61K38/47 , A61K38/57 , C12Y302/01018 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/401 , Y02A50/402 , Y02A50/411 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/478 , Y02A50/48 , Y02A50/483 , Y02A50/491 , Y10T428/2982
摘要： Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
摘要翻译：通过使蛋白质或其他高分子的水溶液与有机溶剂和抗衡离子接触并冷却溶液来制备微球体。微球可用于制备具有限定尺寸的药物。

7. 发明授权

US10085470B2 Method for improving the quality of soy sauce using Bacillus amyloliquefaciens 有权
公开(公告)号：US10085470B2
公开(公告)日：2018-10-02
申请号：US15204991
申请日：2016-07-07
申请人： Fang Fang , Jiran Zhang , Xifei Yang , Chuanwang Hu , Jian Chen , Guocheng Du
发明人： Fang Fang , Jiran Zhang , Xifei Yang , Chuanwang Hu , Jian Chen , Guocheng Du
IPC分类号： A23L5/20 , A23L27/50 , A23L23/00 , C12N1/20 , C12R1/07
摘要： The present invention provides a method for improving the quality of soy sauce using Bacillus amyloliquefaciens, which relates to the field of microbiology and food technology. The method comprises inoculating Bacillus amyloliquefaciens BBE JY06 during soy sauce fermentation. With Bacillus amyloliquefaciens addition during soy sauce fermentation, the aroma and tastes of soy sauce is improved and the ethyl carbamate content in soy sauce is decreased as well.

8. 外观设计

USD827313S1 Fabric swatch 有权
公开(公告)号：USD827313S1
公开(公告)日：2018-09-04
申请号：US29641258
申请日：2018-03-20
申请人： Edward Eng , Fang Fang
设计人： Edward Eng , Fang Fang

9. 发明授权

US08586712B2 Humanized antibodies 失效
公开(公告)号：US08586712B2
公开(公告)日：2013-11-19
申请号：US12748304
申请日：2010-03-26
申请人： Fang Fang , Lori Kohlstaedt , John Reno
发明人： Fang Fang , Lori Kohlstaedt , John Reno
IPC分类号： C07K16/28 , C12N15/13 , C12N15/63 , A61K39/395
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2821 , C07K2317/24 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y02A50/412
摘要： Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of binding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of binding an ICAM-1 epitope are further provided.

10. 发明授权

US08394771B1 Multimeric proteins and methods of making and using same 失效
公开(公告)号：US08394771B1
公开(公告)日：2013-03-12
申请号：US11866960
申请日：2007-10-03
申请人： Fang Fang , Guang-Xiang Luo , Lori Allison Kohlstaedt , Catherine Helen Charles
发明人： Fang Fang , Guang-Xiang Luo , Lori Allison Kohlstaedt , Catherine Helen Charles
IPC分类号： A61K38/17 , C12P21/04 , C07K14/435
CPC分类号： C07K16/2821 , A61K38/00 , C07K14/001 , C07K14/4705 , C07K2319/00 , C07K2319/02 , C07K2319/73 , C12N15/62
摘要： The invention provides multimerization polypeptides capable of conferring formation of multimers when the multimerization polypeptide is linked to a molecule, such as a heterologous polypeptide sequence.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式